HemaCare is the leading global provider of human-derived cellular material, supplying controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. HemaCare supports biotechnology and pharmaceutical companies, academic institutions, and research organization who rely on high-quality, viable, and functional human primary cells and blood components for biomedical and drug discovery research and cell therapy development.
Corporate Reports and Filings
News and Events
Phacilitate Cell & Gene Therapy World
HemaCare will chair and present at Supply Chain Panel Discussion at Phacilitate Leaders World Conference. Dr. Dominic Clarke will be speaking at 1:30 pm on Wednesday, January 23 on “Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for Clinical and Commercial Development.” Be sure to meet up with Dr. Dominic Clarke to discuss your cell therapy needs.READ MORE
HemaCare Relocates Global HeadquartersHemaCare is proud to announce the relocation of its global headquarters to a newly renovated state-of-the-art facility to accommodate its accelerated growth and meet industry demand for high-quality GMP cellular material.READ MORE
HemaCare Provides Starting Material For Three FDA Approved Cellular Therapies40-Years of Blood Collection and Processing Proudly Supporting the Development of Life-Changing MedicinesREAD MORE
HemaCare Details Expanded GMP Capabilities at CAR-TCR Summit in Boston, MAFacility Relocation and Expansion Offers Fully-Integrated GMP Cell Therapy ServicesREAD MORE
Investor Relations Contact Information
(877) 310-0717 (option 8)
250 Royall Street
Canton, MA 02021
The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control, with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
HemaCare voluntarily delisted from NASDAQ in 2012 due to the significant costs of remaining a public company and is no longer required to be registered with the SEC. HemaCare is currently traded on the OTCMKTS (Pink Sheets) under “HEMA”.
Note: It is the policy of HemaCare not to respond to email inquiries via return email. If you have a specific question regarding HemaCare, please call.